AltaRex Provides Update on Reorganization and Capital Injection.Business Editors/Health/Medical Writers EDMONTON, Alberta--(BUSINESS WIRE)--Jan. 19, 2004 AltaRex Corp. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :ALXFF.PK) (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :AXO AXO Asianxo (website) AXO Alpha Chi Omega (sorority) AXO Ach So AXO Access Extension Object ), ("AltaRex" or the "Company"), would like to update shareholders of the proposed transaction involving Nova Bancorp Investments Ltd. ("Nova Bancorp") announced December 3, 2003. On December 22, 2003, the Company received an interim order from the Court of Queen's Bench of Alberta The Court of Queen's Bench of Alberta is the superior court of the Canadian province of Alberta. Structure
Pursuant to the previous announcement, AltaRex and Nova Bancorp entered into an arrangement agreement on December 23, 2003 and the Company will hold a special meeting of securityholders to approve the arrangement on February 2, 2004. All securityholders of record on January 2, 2004 have been mailed the Notice of Special Meeting, Notice of Petition, Management Information Circular and applicable form of proxy. The Company has posted on www.altarex.com a letter to shareholders from Dr. Antoine Noujaim, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , dated January 2, 2004 outlining the proposed transaction. To obtain a copy of the management information circular, letter of transmittal Letter of Transmittal A document used by security holder to accompany certificates surrendered in an exchange or other corporate action. and forms of proxy, please see www.sedar.com. AltaRex is focused on the research, development and commercialization of foreign antibodies that modulate the immune system for the treatment of certain cancers and other diseases where there exists an unmet medical need. Additional information about AltaRex research and development, clinical trials, news and events can be found on the Company website www.altarex.com. This news release contains certain information that may constitute forward-looking statements under applicable securities laws. The reader is cautioned that assumptions used in the preparation of such information, while considered reasonable by the Company at the time of preparation, may prove to be incorrect. Actual results achieved may vary from the results anticipated or implied herein and variations may be material. There is no representation by the Company that actual results achieved will be the same in whole or in part as those implied in any forward looking statements. Neither the TSX nor the TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has approved or disapproved of the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion